Page 39 - Recursion Pharmaceuticals News Today

Ochre Bio’s Series A financing will support development of RNA therapies for chronic liver disease. Longer term, the company aims to develop therapies that regenerate organs in patients, potentially avoiding the need for organ transplants.

Lux Capital, an investment management firm, published its second quarter 2022 investor letter – a copy of which can be downloaded here.

Last week saw significant volatility. However, positive sentiment intensified throughout the biotech space, propelled by favorable legislation and encouraging trial data. 

U.S. stocks closed lower with the Nasdaq Composite dropping over 100 points on Friday. Here is the list of some big stocks recording losses in the...

Arpeggio Biosciences raised $17 million in a Series A funding round led by Builders VC. The startup is focused on measuring the transcriptome — which refers to the full range of mRNA molecules expressed by an organism — to develop better therapeutics.

Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.

In the beginning of July, Cathie Wood of ARK Investment Management admitted that while her predictions about inflation were wrong, the US seems to be heading towards a deflationary environment.

His appointment is effective immediately and he will serve on Alphabet's Audit and Compliance Committee.

Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.

With “low hanging fruit” drugs already in the market, biopharma companies are finding it more difficult to discover the next blockbuster...